sitefansalaran International News

The Kidney Transplant Market is expected to reach at a CAGR of 3.7% during the forecast period 2025-2033. The Global Kidney Transplant Market is witnessing growth due to rising kidney diseases, advanced surgical techniques, and increasing organ donation awareness worldwide.” — DataM Intelligence AUSTIN, TX, UNITED STATES, August 19, 2025 /EINPresswire.com/ -- Overview of the Market: The Global Kidney Transplant Market is experiencing robust growth, driven by the rising prevalence of chronic kidney diseases (CKD), end-stage renal disease (ESRD), and advancements in transplant technology. Kidney transplantation is considered the most effective treatment for patients with ESRD compared to dialysis, offering improved survival rates and quality of life. Increasing awareness about organ donation, government-backed initiatives, and expanding healthcare infrastructure are further boosting the market demand worldwide. According to DataM Intelligence, the Global Kidney Transplant Market was valued at USD 7.91 billion in 2024 and is expected to reach USD 10.99 billion by 2033, expanding at a CAGR of 3.7% between 2025 and 2033. The rising number of kidney failure cases due to diabetes and hypertension has created a high demand for transplants. North America dominates the market owing to advanced healthcare systems, strong regulatory frameworks, and higher organ donation rates, while the living donor transplant...

Endocrinology Drugs revenue is expected to grow at a CAGR of 7.8% from 2025 to 2032, reaching nearly USD 29.88 Bn. by 2032. Endocrinology drugs are at the forefront of medical innovation, improving lives by tackling complex hormonal diseases with precision and expanded access.” — Navneet Kaur ORLANDO, FL, UNITED STATES, August 19, 2025 /EINPresswire.com/ -- Stellar Market Research examines the growth rate of the Endocrinology Drugs Market during the forecasted period 2025-2032 The Endocrinology Drugs Market is projected to grow at a CAGR of approximately 7.8% over the forecast period. The Endocrinology Drugs Market was valued at USD 16.38 billion in 2024 and is expected to reach USD 29.88 billion by 2032. The endocrinology drugs market is driven as more people have these health problems, more people are getting older, new treatments are being made, more people can access healthcare, more copycat drugs are being made, and the quick use of these drugs in new places like the Asia-Pacific. The endocrinology drugs market fixes hormone issues, such as diabetes, thyroid problems, and weak bones, is growing. This rise comes from more people with these disorders, older people, and more people knowing about the issue. Main parts are drugs for diabetes, hormone swaps, and...

Saudi Minister of Health Fahd Al-Jalajel met with the Australian Minister for Health and Aged Care Mark Butler in Canberra on Monday. During the meeting, they discussed ways to enhance bilateral cooperation in the fields of healthcare, digital innovation, and investment in the pharmaceutical industry. During the meeting, both sides affirmed their commitment to strengthening health ties between the two countries and opening new horizons for cooperation. Speaking on the occasion, Al-Jalajel said that the Saudi healthcare sector is witnessing a qualitative transformation within the Kingdom's Vision 2030, focusing on prevention, patient empowerment, and the adoption of value-based care. He noted that the Saudi pharmaceutical and biotechnology market, valued at over $9 billion, represents a promising opportunity for strategic partnerships between the two countries. Trade in healthcare products between the two countries represents 14 percent of the Kingdom's total imports from Australia in 2024, he pointed out. Al-Jalajel also highlighted the Kingdom's leadership in digital health, including the launch of the world's largest virtual hospital, which has provided more than 50 million consultations. He emphasized that cooperation with Australia contributes to accelerating the global adoption of virtual healthcare technologies and building a more efficient, high-quality, and sustainable healthcare future. Al-Jalajel also held bilateral...

Conflicts of interest on the U.S. Centers for Disease Control and Prevention’s vaccine advisory committee were at historic lows around the time when Health Secretary Robert F. Kennedy Jr. fired all 17 members in June, new data published in a medical journal on Monday showed. Kennedy had said, based on findings from a 2007 report, that the Advisory Committee on Immunization Practices (ACIP) was rife with conflicts. The new study published in JAMA found that between 2000 and 2024, ACIP's annual reported conflict of interest rate declined from 42.8% to 5%. ACIP advises on which groups of people should take each vaccine approved by the U.S. Food and Drug Administration, and when they should be administered. Conflict of interest rates on the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which advises the agency on whether to approve vaccines, have remained below 4% since 2010, including 10 years when it was 0%, the researchers also found. The most frequently reported conflict of interest was funding for research, which is generally considered less concerning than financial ties associated with personal income, the researchers said. The prevalence of conflicts related to personal income – such as from consulting, royalties, or stock ownership – had been below...

Medical Tourism Market to reach US$ 605.2 Bn by 2035, growing at 20.1% CAGR, driven by cost savings and advanced healthcare access. WILMINGTON, DE, UNITED STATES, August 15, 2025 /EINPresswire.com/ -- The global medical tourism market, valued at US$ 77.8 Billion in 2024, is projected to grow at a CAGR of 20.1% from 2025 to 2035, reaching US$ 605.2 Billion by the end of 2035, according to Transparency Market Research. Rising healthcare costs in developed nations, combined with access to high-quality medical services at significantly lower prices in developing countries, are fueling robust industry growth. The increasing elderly population, coupled with the growing number of uninsured individuals, is prompting patients to seek affordable yet sophisticated medical treatments abroad. From cosmetic surgeries with quick recovery times to advanced cardiovascular procedures, medical tourism is reshaping global healthcare access while supporting economic development in destination countries. Medical tourism refers to patients traveling internationally for medical treatments ranging from complex procedures such as cardiac surgery, orthopedics, and neurosurgery to elective treatments like cosmetic surgery and dental care. Escalating healthcare expenses in developed economies and the availability of cost-effective, high-quality care in developing nations are major growth drivers. In the United States alone, around 26 million people lacked...

Saudi Arabia Generic Drugs Market is anticipated to grow to US$ 8.11 billion by 2033 from US$ 4.05 billion in 2024, growing at a CAGR of 8.02% during 2025 to 2033. This growth is attributed to increased healthcare needs, government efforts to curb pharmaceutical expenditure, and mounting awareness for cost-effective alternatives. The market is also boosted by growing local manufacturing and government support for generics. Saudi Arabia Generic Drugs Market Overviews Generic drugs are bioequivalent medications that have the same active ingredients, dosage strength, dosage form, and route of administration as their brand-name equivalents but at lower prices. They are licensed by regulatory bodies only after proving their bioequivalence to branded medicines, guaranteeing they have the same therapeutic effects. Generic drugs lower the cost of healthcare substantially and promote access to necessary medication. In Saudi Arabia, the demand for generic medications is increasing at a very high pace. It is fueled by attempts by the government to lower reliance on imported branded medicines and in trying to slash healthcare spending. The Saudi Food and Drug Authority (SFDA) has made the process of generic approvals easier, prompting local and foreign manufacturers to increase their generic offerings. Additionally, public health awareness campaigns and a...

The Global Diabetic Ketoacidosis Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.3 billion by 2030 growing with a CAGR of 5.8% during the forecast period. Diabetic Ketoacidosis Market Report by DataM Intelligence offers a detailed assessment of the global acute-care and diabetes management landscape, highlighting market size, key players, and critical growth drivers. With improvements in hospital DKA pathways, point-of-care testing, and integration of subcutaneous insulin strategies, the report delivers strategic insights for stakeholders from 2025 to 2033. In 2025, major guideline updates (ADA/ADA Standards of Care) clarified transitions from IV to subcutaneous insulin and refined DKA treatment pathways - changes that are already influencing hospital protocols and device/insulin delivery demand in the U.S. acute-care market. The global diabetic ketoacidosis treatment market was valued at USD 3.6 billion in 2024 and is projected to grow from USD 3.8 billion in 2025 to USD 6.4 billion by 2034, registering a CAGR of 6.1% during the forecast period. This growth is primarily driven by the rising prevalence of diabetes, particularly type 1 diabetes, and the increasing adoption of advanced insulin delivery systems. Innovations such as automated insulin pumps and continuous glucose monitoring (CGM) technologies are enhancing treatment precision...

White House trade adviser Peter Navarro said on Thursday that the Trump administration is likely to levy tariffs on pharmaceutical imports under a "Section 232" trade investigation because it's "very clear that we have a national security crisis" due to U.S. reliance on foreign producers in the sector. In an televised interview with CNBC, Navarro did not provide any details on the timing of the Section 232 probe. He said that President Donald Trump's executive order to shore up supply chains will provide price floors for domestic producers of drug ingredients through long-term strategic contracts that will ensure sufficient demand. At the same time, tariffs will deter dumping of pharma precursors from India and China, he added.

The Saudi Arabia Pharmacy Retail Market offers growth opportunities driven by a rising demand for healthcare services linked to a growing aging population and chronic diseases like diabetes and cardiovascular conditions. Government initiatives and the expansion of online pharmacies further fuel market growth, promoting convenience and accessibility. The Saudi Arabia Pharmacy Retail Market was valued at USD 7.34 Billion in 2024 and is expected to reach USD 12.67 Billion by 2030, rising at a CAGR of 9.53%. The Saudi Arabia Pharmacy Retail market is primarily driven by several key factors, including the increasing demand for healthcare services, particularly due to the country's growing and aging population. Chronic diseases like diabetes, cardiovascular conditions, and respiratory illnesses are becoming more prevalent, leading to a higher demand for pharmaceutical products. As a part of this, according to a recent study, as of 2024, diabetes has emerged as a significant public health issue, with an estimated 18.5% of Saudi individuals having the disease. Also, government initiatives like Vision 2030 aim to improve the overall healthcare infrastructure, driving growth in the retail pharmacy sector. The rise in health awareness among consumers and a shift towards self-medication also contribute to market expansion. Additionally, the increasing availability of online...

The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on its exports, two sources have told Reuters. Economy Minister Guy Parmelin and Health Minister Elizabeth Baume-Schneider will meet with executives from Roche (ROG.S), opens new tab and Novartis (NOVN.S), opens new tab, according to two people familiar with the matter, who said other companies may also take part. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Roche and Novartis did not respond to a request for comment. A spokesperson for the health minister confirmed the meeting but declined to give any details or confirm the participants. Although pharmaceuticals are not included in the 39% U.S. tariffs which came into effect on Swiss imports last week, the industry is concerned by the outcome of the U.S. Section 232 national security investigation into the sector. This could result in tariffs on drug imports eventually reaching 250%. The results of the review are expected in the next few weeks. The talks could also be about encouraging pharmaceuticals companies to invest more in the...